Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer

Endocrine-Related Cancer

Volumn 12, Issue SUPPL. 1, 2005, Pages

  Gee, J M ^a   Robertson, J F ^b   Gutteridge, E ^b   Elis, I O ^b   Pinder, S E ^b   Rubini, M ^c   Nicholson, R I ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SOMATOMEDIN RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

BREAST CANCER; CANCER MODEL; CONFERENCE PAPER; ESTROGEN ACTIVITY; HORMONAL THERAPY; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ESTROGEN ANTAGONISTS; ESTROGENS; FEMALE; HUMANS; PHOSPHORYLATION; RECEPTOR CROSS-TALK; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, SOMATOMEDIN; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 25844468319     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.01005     Document Type: Conference Paper

References (49)

1. Arpino G, Green SJ, Allred DC, Lew D, Martine S, Osborne CK & Elledge RM 2004 HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. Clinical Cancer Research 10 5670-5676.
2. Bartucci M, Morelli C, Mauro L, Ando S & Surmacz E 2001 Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells. Cancer Research 61 6747-6754.
3. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM & Osborne CK 1993 Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Research and Treatment 24 85-95.
4. Biswas DK, Cruz AP, Gansberger E & Pardee AB 2000 Epidermal growth factor-induced nuclear factor kappa B activation: a major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. PNAS 97 8542-8547.
5. Chen D, Washbrook E, Sarwar N, Bates GJ, Pace PE, Thirunuvakkarasu V, Taylor J, Epstein RJ, Fuller-Pace FV, Egly JM, Coombes RC & Ali S 2002 Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene 21 4921-4931.
6. Dowsett M, Harper-Wynne C, Boeddinghaus I, Salter J, Hills M, Dixon M, Ebbs S, Gui G, Sacks N & Smith I 2001 HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Research 61 8452-8458.
7. Elledge RM, Green S, Ciocca D, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P, O'Sullivan J, Martino S & Osborne CK 1998 HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clinical Cancer Research 4 7-12.
8. Ellis MJ, Coop A, Singh B, Tao Y, Llombart-Cussac A, Janicke F, Mauriac L, Quebe-Fehling E, Chaudri-Ross HA, Evans DB & Miller WR 2003 Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Research 63 6523-6531.
9. Gee JM, Willsher PC, Kenny FS, Robertson JF, Pinder SE, Ellis IO & Nicholson RI 1999 Endocrine response and resistance in breast cancer: a role for the transcription factor Fos. International Journal of Cancer 84 54-61.
10. Gee JM, Robertson JF, Ellis IO & Nicholson RI 2001 Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to antihormonal therapy and decreased patient survival in clinical breast cancer. International Journal of Cancer 4 247-254.
11. Gee JMW, Rubini M, Robertson JF, Ellis IO, Gutteridge E & Nicholson RI 2003 Type 1 insulin-like growth factor receptor expression and activation in clinical breast cancer. Breast Cancer Research and Treatment 82 S102.
12. Guvakova MA & Surmacz E 1997 Tamoxifen interferes with the insulin-like growth factor I receptor signaling pathway in breast cancer cells. Cancer Research 57 2606-2610.
13. Hamelers IH & Steenbergh PH 2003 Interactions between estrogen and insulin-like growth factor signaling pathways in human breast tumor cells. Endocrine-Related Cancer 10 331-345.
14. Happerfield LC, Miles DW, Barnes DM, Thomsen LL, Smith P & Hanby A 1997 The localization of the insulin-like growth factor receptor 1 (IGFR-1) in benign and malignant breast tissue. Journal of Pathology 183 412-417.
15. Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD & Miles DW 1999 Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. British Journal of Cancer 79 1220-1226.
16. Hutcheson IR, Gee JMW & Nicholson RI 2003a MAP kinase family members and endocrine response and survival in breast cancer. In Prognostic and Predictive Factors in Breast Cancer, pp 147-190. Ed RA Walker. London: Martin Dunitz.
17. Hutcheson IR, Knowlden JM, Madden TA, Barrow D, Gee JM, Wakeling AE & Nicholson RI 2003b Estrogen receptor mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Research and Treatment 81 81-93.
18. Johnston S 2004 Fulvestrant and the sequential endocrine cascade for advanced breast cancer. British Journal of Cancer 90 S15-S18.
19. 2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clinical Cancer Research 5 251-256.
20. Johnston SR, Head J, Pancholi S, Detre S, Martin LA, Smith IE & Dowsett M 2003 Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. Clinical Cancer Research 9 524S-532S.
21. Kenny FS, Finder S, Ellis IO, Gee JMW, Nicholson RI, Bryce RP & Robertson JFR 2000 Gamma linolenic acid with tamoxifen as primary therapy in breast cancer. International Journal of Cancer 85 643-648.
22. Kenny FS, Willsher PC, Gee JM, Nicholson R, Pinder SE, Ellis IO & Robertson JF 2001 Change in expression of ER, bcl-2 and MIB1 on primary tamoxifen and relation to response in ER positive breast cancer. Breast Cancer Research and Treatment 65 135-144.
23. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE & Nicholson RI 2003 Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144 1032-1044.
24. Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H & Slamon DJ 2003 Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. Journal National Cancer Institute 95 142-153.
25. Kurokawa H & Arteaga CL 2003 ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clinical Cancer Research 9 511S-515S.
26. Lannigan DA 2003 Estrogen receptor phosphorylation. Steroids 68 1-9.
27. Lipton A, Leitzel K, Ali SM, Demers L, Harvey HA, Chaudri-Ross HA, Lang R, Hackl W, Hamer P & Carney W 2003 Serum HER-2/neu conversion to positive at the time of cancer progression in metastatic breast patients treated with letrozole vs. tamoxifen. Proceedings of the American Society of Clinical Oncology 22 3 (Abstract 8).
28. Lonn U, Lonn S, Ingelman-Sundberg H, Nilsson B & Stenkvist B 1996 C-erb-b2/int-2 amplification appears faster in breast-cancer patients receiving second-line endocrine treatment. International Journal of Cancer 69 273-277.
29. Lovekin C, Ellis IO, Locker A, Robertson JF, Bell J, Nicholson R, Gullick WJ, Elston CW & Blamey RW 1991 c-erbB-2 oncoprotein expression in primary and advanced breast cancer. British Journal of Cancer 63 439-443.
30. Murphy L, Cherlet T, Adeyinka A, Niu Y, Snell L & Watson P 2004a Phospho-serine-118 estrogen receptor-alpha detection in human breast tumors in vivo. Clinical Cancer Research 10 1354-1359.
31. Murphy LC, Niu Y, Snell L & Watson P 2004b Phosphoserine-118 estrogen receptor-alpha expression is associated with better disease outcome in women treated with tamoxifen. Clinical Cancer Research 10 5902-5906.
32. Nicholson RI, McClelland RA, Finlay P, Eaton CL, Gullick WJ, Dixon AR, Robertson JF, Ellis IO & Blamey RW 1993 Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. European Journal of Cancer 29A 1018-1023.
33. Nicholson RI, McClelland RA, Gee JM, Manning DL, Cannon P, Robertson JF, Ellis IO & Blamey RW 1994a Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Research and Treatment 29 117-125.
34. Nicholson RI, McClelland RA, Gee JM, Manning DL, Cannon P, Robertson JF, Ellis IO & Blamey RW 1994b Transforming growth factor-alpha and endocrine sensitivity in breast cancer. Cancer Research 54 1684-1689.
35. Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, Jordan N, Hiscox SE, Barrow D & Gee JM 2004a Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clinical Cancer Research 10 346S-354S.
36. Nicholson RI, Jones HE & Gee JMW 2004b EGFR inhibitors in breast cancer. Signal 5 (3) 9-13 (online publication).
37. Nicholson RI, Staka C, Boyns F, Hutcheson IR & Gee JM 2004c Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy. Endocrine-Related Cancer 11 623-641.
38. Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG & El-Ashry D 2001 Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. Molecular Endocrinology 15 1344-1359.
39. Parisot JP, Hu XF, DeLuise M & Zalcberg JR 1999 Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line. British Journal of Cancer 79 693-700.
40. Railo MJ, von Smitten K & Pekonen F 1994 The prognostic value of insulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients. European Journal of Cancer 30A 307-311.
41. Robertson JFR, Gutteridge E, Cheung KL, Owers R, Koehler M, Hamilton L, Gee J & Nicholson RI 2003 Gefitinib (ZD 1839) is active in acquired tamoxifen (TAM)-resistant estrogen receptor (ER)-positive and ER-negative breast cancer: results from a phase II study. Proceedings of the American Society of Clinical Oncology 22 7 (23A).
42. Rocha RL, Hilsenbeck SG, Jackson JG, VanDenBerg CL, Weng C, Lee AV & Yee D 1997 Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clinical Cancer Research 3 103-109.
43. Sharma AK, Horgan K, Douglas-Jones A, McClelland R, Gee J & Nicholson R 1994 Dual immunocytochemical analysis of oestrogen and epidermal growth factor receptors in human breast cancer. British Journal of Cancer 69 1032-1037.
44. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H & Schiff R 2004 Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. Journal of the National Cancer Institute 96 926-935.
45. Stoica A, Saceda M, Doraiswamy VL, Coleman C & Martin MB 2000 Regulation of estrogen receptor-alpha gene expression by epidermal growth factor. Journal of Endocrinology 165 371-378.
46. Thor AD, Liu S, Edgerton S, Moore D 2nd, Kasowitz KM, Benz CC, Stern DF & DiGiovanna MP 2000 Activation (tyrosine phosphorylation) of ErbB2 (HER2/neu): a study of incidence and correlation with outcome in breast cancer. Journal of Clinical Oncology 18 3230-3239.
47. Tsutsui S, Ohno S, Murakami S, Hachitanda Y & Oda S 2002 Prognostic value of epidermal growth factor receptor and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Research and Treatment 71 67-75.
48. Turner BC, Haffty BG, Narayanan L, Yuan J, Havre PA, Gumbs AA, Kaplan L, Burgaud JL, Carter D, Baserga R & Glazer PM 1997 Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Research 57 3079-3083.
49. Wiseman LR, Johnson MD, Wakeling AE, Lykkesfeldt AE, May FE & Westley BR 1993 Type IIGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cells. European Journal of Cancer 29A 2256-2264.